SpringWorks Therapeutics, Inc. SWTX
At closeJul 1, 2025, 4:00 PM EDT
52-week range unavailable
- Market cap
- 3.54B
- Revenue (ttm)
- 219.67M
- Profit margin
- -115.60%
- Shares out
- 75.35M
- Forward P/E
- -21.96
- Volume
- 5.01M
- Open
- 46.99
- Previous close
- 46.99
- Day's range
- 46.99 – 46.99
- Beta
- 0.70
- Price target
- 47.00 (+0.0%)
Key statistics
- Enterprise value
- 3.26B
- PEG ratio
- 0.00
- Price / sales
- 16.12
- Price / book
- 8.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 133.70%
- Free cash flow
- -94.37M
- Total cash
- 287.87M
- Total debt
- 7.39M
- Return on equity
- -51.57%
- Short % of float
- 10.18%
- 50-day average
- 46.50
- 200-day average
- 41.63
Analyst view
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.97.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 12, 2025 | Guggenheim | reit | Neutral | Neutral |
| Apr 30, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 29, 2025 | Guggenheim | down | Buy | Neutral |
| Apr 29, 2025 | TD Cowen | down | Buy | Hold |
| Apr 28, 2025 | Barclays | down | Overweight | Equal-Weight |
| Feb 24, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial. In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- springworkstx.com
News
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology 
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology 
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors 
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors 
Immunome: SpringWorks Buyout Informs The Potential Upside Here 
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business 
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors 
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
Your note
Sign in to keep a note on SWTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALBAN CARLOS | Director | Stock Award(Grant) | May 13, 2025 | 28,861 |
| ASHAR BHAVESH | Officer | Sale | Feb 19, 2025 | 62,053 |
| EDRIS BADREDDIN | Chief Operating Officer | Sale | Mar 2, 2025 | 169,712 |
| FUHRMAN ALAN | Director | Stock Award(Grant) | May 13, 2025 | 24,727 |
| HAMBLETON JULIE | Director | Stock Award(Grant) | May 13, 2025 | 14,155 |
| ISLAM SAQIB | Chief Executive Officer | Sale | Mar 2, 2025 | 954,869 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.87% | 11,204,799 | 526.51M | Mar 30, 2025 |
| Vanguard Group Inc | 9.40% | 7,082,581 | 332.81M | Mar 30, 2025 |
| Blackrock Inc. | 8.29% | 6,246,071 | 293.50M | Mar 30, 2025 |
| State Street Corporation | 3.87% | 2,916,341 | 137.04M | Mar 30, 2025 |
| Price (T.Rowe) Associates Inc | 3.43% | 2,582,732 | 121.36M | Mar 30, 2025 |
| Woodline Partners LP | 2.85% | 2,144,814 | 100.78M | Mar 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.04% | 2,292,607 | 107.73M | Mar 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.36% | 1,777,475 | 83.52M | Mar 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.25% | 1,694,201 | 79.61M | Apr 29, 2025 |
| SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF | 1.76% | 1,326,035 | 62.31M | Apr 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.51% | 1,141,283 | 53.63M | Mar 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.32% | 997,165 | 46.86M | Mar 30, 2025 |